|[March 19, 2013]
Research and Markets: PharmaPoint: Prostate Cancer - Italy Drug Forecast and Market Analysis to 2022
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/6rwbsz/pharmapoint)
has announced the addition of the "PharmaPoint:
Prostate Cancer - Italy Drug Forecast and Market Analysis to 2022"
report to their offering.
The recent approvals of second-line metastatic castration-resistant
prostate cancer (mCRPC) therapies like J&J's Zytiga (abiraterone
acetate) and Medivation/Astellas' Xtandi (enzalutamide) will drive
strong market growth over the next decade. These safe and orally
administered treatments will provide safety and convenience benefits
over the current standard of care, chemotherapy with docetaxel, while
prolonging the overall survival of patients with mCRPC. The December 12,
2012 FDA approval of Zytiga for the added indication of
chemotherapy-naïve mCRPC marks the onset of a new treatment paradigm for
the disease, in which chemotherapy is relegated to second-line therapy
and beyond. For patients with earlier-stage prostate cancer, androgen
deprivation therapy with LHRH agonists and first-generation
antiandrogens remains the stanard of care for suppressing testosterone
levels and temporarily controlling the disease.
In Italy, prostate cancer is diagnosed in response to symptoms, an
abnormal DRE, or an elevated PSA level found during routine screening
(EAU, 2012). Routine PSA screening is used less frequently in Italy than
in most major markets, similar to the UK. A diagnosis is confirmed using
TRUS-guided core needle biopsies, and metastases are detected using a
bone scan, CT scan, or Positron Emission Tomography (PET) choline scan.
Prescribers and KOLs do not expect to see major changes in how prostate
cancer is diagnosed over the forecast period, and do not believe the
USPSTF recommendation against routine PSA screening will have an impact
- Overview of RA, including epidemiology, etiology, symptoms, diagnosis,
pathology and treatment guidelines as well as an overview on the
- Detailed information on the key drugs in Italy including product
description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Italy from 2012 to 2022.
- Analysis of the impact of key events as well the drivers and
restraints affecting the Italy Prostate cancer market.
Reasons to Buy
- Understand and capitalize by identifying products that are most likely
to ensure a robust return
- Stay ahead of the competition by understanding the changing
competitive landscape for Prostate cancer
- Effectively plan your M&A and partnership strategies by identifying
drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth
analysis of Prostate cancer drug performance in Italy
- Obtain sales forecast from 2012-2022 in Italy
Key Topics Covered
1 List of Tables and of Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Opportunity and Unmet Need
7 Pipeline Assessment
8 Market Outlook
For more information visit http://www.researchandmarkets.com/research/6rwbsz/pharmapoint
[ Back To Technology News's Homepage ]